4D Molecular Therapeutics (FDMT) EBITDA Margin (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted EBITDA Margin of -2003.31% for Q2 2026, up 386596.69 percentage points from -388600.00% a year earlier and up 371.19 percentage points from the prior quarter.
4D Molecular Therapeutics (FDMT) EBITDA Margin (2020 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, EBITDA Margin at 4D Molecular Therapeutics was -208.77%, up 653800.32 percentage points year-over-year; for FY2025, it was -181.73%, up 494920.97 percentage points from FY2024.
- Annual EBITDA Margin shows a five-year change of +223.95 percentage points (FY2020 to FY2025).
- In prior years, 4D Molecular Therapeutics' EBITDA Margin was -495102.70% in FY2024 (-494578.34 pp), -524.36% in FY2023 (+2915.37 pp), -3439.73% in FY2022 (-3052.71 pp) and -387.02% in FY2021 (+18.66 pp).
- Quarterly EBITDA Margin has run from a low of -5502100.00% in Q4 2024 to a high of 18.72% in Q4 2025 over five years.
- On a year-over-year basis, EBITDA Margin has increased in each of the last five quarters, with an average year-over-year change of +912639.09 percentage points over the last seven quarters.
- The strongest year-over-year quarter for EBITDA Margin in the past five years was Q4 2025, with a gain of 5502118.72 percentage points; the weakest was Q3 2024, with a drop of 1664669.09 percentage points.
- According to Business Quant data, EBITDA Margin for the three prior quarters was -2374.50% (Q1 2026), 18.72% (Q4 2025) and -66582.22% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | 4D Molecular Therapeutics | 1.02 Bn | -436.78 Mn | - | -2,003.31% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,003.31% |
| Mar 31, 2026 | -2,374.50% |
| Dec 31, 2025 | 18.72% |
| Sep 30, 2025 | -66,582.22% |
| Jun 30, 2025 | -388,600.00% |
| Mar 31, 2025 | -375,500.00% |
| Dec 31, 2024 | -5,502,100.00% |
| Sep 30, 2024 | -1,664,733.33% |
| Jun 30, 2024 | -825,240.00% |
| Mar 31, 2024 | -132,010.71% |
| Sep 30, 2023 | -64.24% |
| Jun 30, 2023 | -12,994.56% |
| Mar 31, 2023 | -9,757.38% |
| Dec 31, 2022 | -2,221.81% |
| Sep 30, 2022 | -5,195.60% |
| Jun 30, 2022 | -17,259.26% |
| Mar 31, 2022 | -2,131.75% |
| Dec 31, 2021 | -26,493.48% |
| Sep 30, 2021 | -1,631.11% |
| Jun 30, 2021 | -49.56% |
4D Molecular Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=FDMT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "FDMT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=FDMT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();